Treatment of Experimental Intracranial Murine Melanoma with a Neuroattenuated Herpes Simplex Virus 1 Mutant

Virology

Volumn 211, Issue 1, 1995, Pages 94-101

  Randazzo, Bruce P ^a,b   Kesari, Santosh ^a,b   Gesser, Richard M ^a,c   Alsop, David ^b   Ford, John C ^b   Brown, S Moira ^d   Maclean, Alasdair ^d   Fraser, Nigel W ^a  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d INSTITUTE OF VIROLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ARTICLE; BRAIN CANCER; CONTROLLED STUDY; EXPERIMENTAL MELANOMA; FEMALE; HERPES SIMPLEX VIRUS 1; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS REPLICATION;

ANIMAL; ANTIGENS, VIRAL; BRAIN NEOPLASMS; CELL LINE; FEMALE; HAMSTERS; HERPESVIRUS 1, HUMAN; HUMAN; KIDNEY; MAGNETIC RESONANCE IMAGING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SUPPORT, NON-U.S. GOV'T; VACCINES, ATTENUATED; VIRAL VACCINES;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 1; MURINAE;

EID: 0029113725     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1006/viro.1995.1382     Document Type: Article

References (39)

1. Ace, C. I., McKee, T. A., Ryan, J. M., Cameron, J. M., and Preston, C. M. (1989). Construction and characterization of a herpes simplex virus type 1 mutant unable to transinduce immediate early gene expression, J. Virol. 63, 2260-2269.
2. Ackermann, M., Longnecker, R„ Roizman, B., and Pereira, L. (1986). Identification, properties, and gene location of a novel glycoprotein specified by herpes simplex virus. J Virology 150, 207-220.
3. Amer, M. H., Al-Sarraf, M., Baker, L. H., and Vaitkevicius, V. K. (1978). Malignant melanoma and central nervous system metastases: Incidence, diagnosis, treatment and survival. Cancer 42, 660-668.
4. Balch, C. M., Soong, S.-j., Murad, T. M., Smith, J. W., Maddox, W. A., and Durant, J. R. (1983). A multifactoriaI analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J. Clin. Oncol. 1, 126-132.
5. Bleehen, S. S. (1974). Ultra structural studies on tumors and cell cultures of the Harding-Passey mouse melanoma. Br. J. Dermatol. 90, 637-648.
6. Bolovan, C. A., Sawtell, N. M., and Thompson, R. L. (1994). ICP 34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures. J. Virol. 68, 48-55.
7. Budman, D. R., Camacho, E., and Wittes, R. E. (1978). The current causes of death in patients with malignant melanoma. Eur. J, Cancer 14, 327-330.
8. Castillo, R., Diaz, J. W., Veloso, A., and Gavilondo, J. (1982). Leukemoid reaction induced by different transplantable tumors in three inbred mouse strains. Neoplasma 29, 73-79.
9. Chou, J., Kern, E. R., Whitley, R. J., and Roizman, B. (1990). Mapping of herpes simplex virus neurovirulence to gamma 1 34.5, a gene nonessential for growth in culture. Science 250, 1262-1266.
10. Coen, D. M., Fleming, H. E., Jr., Leslie, L. K., and Retondo, M. J. (1985). Sensitivity of arabinosyladenine-resistant mutants of herpes simplex virus to other antiviral drugs and mapping of drug hypersensitivity mutations to the DNA polymerase locus. J. Virol. 53, 477-488.
11. Coen, D. M., Kosz-Vnenchak, M., Jacobson, J. G., Leib, D. A., Bogard, L, Schaffer, P. A., Tyler, K. L, and Knipe, K. M. (1989). Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc. Natl. Acad Sci. USA 86, 4736-4740.
12. t and Hutchins, G. M. (1983). Patterned distribution of metastases from malignant melanoma in humans. Cancer Res. 43, 3427-3433.
13. Doherty, P. C. (1993). Roles of alpha beta and gamma delta T cell subsets in viral immunity. Semin. Virol. 4, 117-138.
14. Dupressoir, T., Vanacker, J.-M., Cornelis, J. J., Duponchel, N., and Rom-melacre, J. (1989), Inhibition by parvovirus H-1 of the formation of tumors in nude mice and colonies in vitro by transformed human mammary epithelial cells. Cancer Res. 49, 3203-3208.
15. Einhorn, L. H., Burgess, M. A., Vallejos, C., Bodey, S. G. P., Gutterman, J., and Mavligit, G. (1974). Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res. 34, 1995-2011.
16. Feun, L. G., Gutterman, J., Burgess, M. A., Hersh, E. M., Mavligit, G., McBride, C. M., Ben amin, R. S., Richman, S. P., Murphy, W. K., Bodey, G. P., Brown, B. W., Mountain, C. F., Leavens, M. E., and Freireich, E. J. (1982). The natural history of resectable metastatic melanoma (Stage IVA melanoma). Cancer 50, 1656-1663.
17. Fidler, I. J. (1973). Selection of successive tumor cell lines for metastasis. Nature 242, 148-149.
18. Garcia-Borron, J. C., Solano, F., Iborra, J. L, and Lozano, J. A. (1985). Aggregation equilibria of tyrosinase of Harding-Passey mouse melanoma. Biochem. j. 228, 95-101.
19. Javier, R. T., Thompson, R. L„ and Stevens, J. G. (1987). Genetic and biological analyses of a herpes simplex virus intertypic recombinant reduced specifically for neurovirulence. J. Virol. 61, 1978-1984.
20. Lopez-Ballester, j. A., Penafiet, R., Cremades, A., Valcarcel, M. M., Solano, F., and Lozano, J. A, (1991). Effects of treatment with alpha-difluoromethylornithine and hyperthermia on the growth and polyamine metabolismof Harding-Passey murine melanoma. Anticancer Res. (Greece) 11, 691-696.
21. MacLean, A. R., Ul-Fareed, M., Robertson, L, Harland, J., and Brown, S. M. (1991). Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the ’a’ sequence. J. Gen. Virol. 72, 631-639
22. Marked, J. M., Coen, D. M., Malick, A., Mineta, T., and Martuza, R. L. Expanded spectrum of viral therapy in the treatment of nervous system tumors. J. Neurosurg. 77, 590-594.
23. Marked, J. M., Malick, A., Coen, D. M., and Martuza, R. L. (1993). Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 32, 597-603.
24. Maduza, R. L., Malick, A., Marked, J. M., Ruffner, K. I., and Coen, M. (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854-856.
25. McGeoch, D. J., Cunningham, C., McIntyre, G., and Dolan, A. (1991). Comparative sequence analysis of the long repeat regions and adjoining pads of the long unique regions in the genomes of herpes simplex viruses types 1 and 2. J. Gen. Virol. 69, 1531-1574.
26. Nash, A. A., Leung, K.-N., and Wildy, P. (1985). The T-cell-mediated immune response of mice to herpes simplex virus. In ‘The Herpesviruses. Immunobiology and Prophylaxis of Human Herpesvirus infections" (B. Roizman and C. Lopez, Eds.). Plenum, New York.
27. Patel, J. K., Didolkar, M. S., Pickren, J. W., and Moore, R. H. (1978), Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am. J. Surg. 135, 807-810.
28. Ram, S., Culver, K. W., Wallbridge, S., Blaese, R. M., and Oldfield, E. H. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53, 83-88
29. Reichard, K. W., Lorence, R. M., Cascino, C. J., Peeples, M. E., Walter, R. J., Fernando, M. B., Beyes, H. M., and Greager, J. A. (1992). Newcastle disease virus selectively kills human tumor cells. J. Surg. Res. 52, 448-453.
30. Roizman, B. (1990). Herpes simplex viruses, in "Fields Virology" (B. N. Fields, D. M. Knipe, R. M. Chanock, M. S. Hirsch, J. L. Melnick, T. P. Monath, and B. Roizman, Eds.). Raven Press, New York.
31. Rouse, B, T.p and Lopez, C. (1984). Role of adaptive immune defense mechanisms in herpes simplex resistance. In "Immunobiology of Herpes Simplex Virus Infection," pp. 131-144, CRC Press, Boca Raton, FL.
32. Schwabe, K., Fichtner, I., and Tschiersch, B. (1990). Non-selective action of 4-hydroxyanisole on melanoma cells in vivo. Pigm. Cell Res. (Denmark) 3, 8-10.
33. Spivack, J. G., and Fraser, N. W. (1987). Detection of herpes simplex type 1 transcripts during latent infection in mice. J. Virol. 61, 3841-3847.
34. Steck, P. A., and Nicolson, G. L. (1993). Metastases to the central nervous system. In "Molecular Genetics of Nervous System Tumors" (A. J. Levine and H. H. Schmidek, Eds.). Wiley-Liss, New York.
35. Taha, M. Y., Brown, S. M., Clements, G. B., and Graham, D. I. (1990). The JH2604 deletion variant of herpes simplex virus type 2 (HG52) fails to produce necrotizing encephalitis following intracranial inoculation of mice. J. Gen. Virol. 71, 1597-1501.
36. Takamiya, Y., Short, M. P., Moolten, F. L., Fleet, C., Mineta, R., Breake-field, X. O., and Martuza, R. L. (1993). An experimental model of retrovirus gene therapy for malignant brain tumors. J. Neurosurg. 79, 104-110.
37. Tenser, R. B. (1991). Role of herpes simplex virus thymidine kinase expression in viral pathogenesis and latency, intervirology 32, 76-92.
38. Vicente, V., Gomez, M., Gomez, S., Calderon, F., Canteras, M., and Cremades, A. (1987). Thermotherapy for Harding-Passey melanoma: Light and electron microscopy study. Histol. Histopathol. 2, 369-381.
39. Yasamura, Y., Tashjian, A. H., Jr., and Sato, G. H. (1966). Establishment of four functional, clonal strains of animal cells in culture. Science 154, 1186-1189.